Journal of Clinical Oncology
Articles in this Issue
ctDNA beyond blood: Harnessing pleural effusion circulating tumor DNA for precision lung cancer diagnostics.
e20029 Background: Tissue biopsy-derived DNA has long been the gold standard for tumor-specific genomic profiling. Similarly, genomic profiling using circ...
Artificial intelligence (XGBoost) in predicting outcomes among CAR-T therapy patients: The impact of malnutrition and comorbidities using the National Inpatient Sample (2020-2022).
2536 Background: Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized hematologic malignancy treatment but remains costly, with limited acc...
Drug sensitivity patterns across FAB subtypes and molecular mutations in AML.
e18507 Background: The study analyzed drug response patterns in 186 AML patients utilizing selective Drug Sensitivity Scores (sDSS) derived from ex vivo m...
Delayed immune-related adverse events associated with immune checkpoint inhibitors: A pharmacovigilance analysis of the FAERS database.
e24093 Background: Treatment with immune checkpoint inhibitors (ICIs) has achieved extraordinary response rates and revolutionized the systematic manageme...
Enhancing breast cancer awareness through artificial intelligence: Bridging the gap for low-literacy populations.
e13519 Background: Breast cancer poses a significant threat to women's health, as evidenced by the alarming statistics that it is the second most common f...
A single center experience of male breast cancer.
e23319 Background: Male breast cancer (BC) is rare, accounting for less than 1% of all breast cancers. The current study is designed to evaluate patient c...
Outcomes of patients treated with dabrafenib and trametinib who developed pyrexia syndrome and severe/complicated pyrexia syndrome.
e24092 Background: The combination of dabrafenib and trametinib has been used to treat many malignancies featuring BRAF mutations. The most common adverse...
Meta-analysis and systematic review of radiomics imaging for predicting pathological complete response to neoadjuvant therapy in esophageal squamous cell carcinoma.
e16083 Background: Esophageal cancer remains a leading cause of cancer related mortality worldwide, with esophageal squamous cell carcinoma (ESCC) being t...
A phase II, open-label study to improve compliance and time of treatment after obtaining complete response (CR) through a tailored schedule of sonidegib in locally advanced basal cell carcinomas (laBCC): The SONIBEC trial.
9540 Background: Sonidegib is an efficacious treatment of LA laBCC but is associated with a high risk of treatment-related adverse events (TRAEs) causing...
Celecoxib vs placebo in combination with chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials.
e20666 Background: Non-small cell lung cancer (NSCLC) is the leading cause of lung cancer-related mortality, with chemotherapy remaining a cornerstone of...
Systemic antitumor virotherapy: Pre-clinical evaluation of tumor targeting, efficacy, and safety of lead candidate (CLD-401).
2593 Background: Systemic antitumor virotherapies are a promising modality of cancer immunotherapy. However, challenges include quick virus clearance from...
Diagnostic performance of artificial intelligence–based computed tomography methods in detecting pancreatic cancer: A systematic review and meta-analysis.
e16372 Background: Pancreatic cancer is among the deadliest tumors. Artificial intelligence (AI) methods could enhance the identification of pancreatic le...
Regional trends in incidence and prevalence of pancreatic cancer among older adults (70+): A 30-year global burden of disease analysis (1990–2021).
e16419 Background: Pancreatic cancer remains one of the most lethal malignancies worldwide. While high-income regions have long faced higher rates, recent...
Efficacy and safety of neoadjuvant toripalimab plus axitinib in renal cell carcinoma with tumor thrombus: A combined analysis of two phase II trials.
4535 Background: Tumor thrombectomy for renal cell carcinoma (RCC) with tumor thrombus (TT) is associated with high morbidity and mortality. Two trials ha...
Presentation, progression, and survival in placental site trophoblastic tumors: A population-based analysis and review of the literature.
e17658 Background: Placental Site Trophoblastic Tumors (PSTT) are an extremely rare subtype of Gestational Trophoblastic Disease (GTD), accounting for 0.2...
EphA2 siRNA in DOPC nanoliposomes (EPHARNA): A phase I clinical trial in patients with solid tumors.
3086 Background: EphA2 overexpression is common in human cancers and has an important role in promoting tumor growth and m...
Prognostic significance of VISTA expression in patients with malignant pleural mesothelioma treated with nivolumab: Results of a retrospective multi-institutional analysis (HOT1901).
8083 Background: Nivolumab as a second-line treatment for pleural mesothelioma (PM) has demonstrated efficacy in the MERIT phase 2 trial in Japan and the...
Performance assessment of an algorithm-based decision-making platform for patient prioritization during cancer care.
e13639 Background: More than 75% of patients receiving cancer treatment suffer Adverse Events (AE), and more than 45% develops at least one severe AE. Rem...
Leveraging AI to enhance symptom capture and reduced hospitalizations.
1572 Background: Unplanned hospitalizations and ED visits for cancer patients impose significant morbidity, financial costs, and reduced quality-of-life....
Telisotuzumab adizutecan (ABBV-400; Temab-A) monotherapy vs trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer with increased c-Met protein expression: An open-label, randomized, phase 3 trial.
TPS3635 Background: c-Met protein expression is increased in several solid tumors, including colorectal cancer (CRC). Temab-A is a c-Met–directed antibody...
Development and real-world validation of a multi-modal machine learning model to predict response to immune checkpoint inhibitors in cancer patients.
e14532 Background: Immune checkpoint inhibitors (ICIs) have transformed cancer care, offering the promise of durable, life-changing responses for cancer p...
The impact of ovarian function suppression with adjuvant endocrine therapy on survival outcomes in young germline <i>BRCA</i> mutation carriers with breast cancer: Secondary analysis of an international cohort study.
507 Background: In young women with hormone receptor-positive (HR+) breast cancer (BC), ovarian function suppression (OFS) has been shown to improve outco...
Tagraxofusp and low-intensity chemotherapy for the treatment of CD123-positive relapsed or refractory acute myeloid leukemia.
TPS6582 Background: The combination of venetoclax and a hypomethylating agent (Ven/HMA) is the standard frontline (1L) therapy for patients with acute mye...
Outcomes and prognostic factors in breast cancer patients with leptomeningeal metastasis: Insights from a retrospective analysis.
e14002 Background: Leptomeningeal metastasis (LM) is a rare and aggressive complication of breast cancer (CA) associated with poor survival. This study ai...
Bridging the gender gap in cancer care at a resident-led federally qualified health center: Retrospective insights and strategies for improvement.
e13841 Background: Federally Qualified Health Centers (FQHCs) are nonprofit organizations with federal funding which play a vital role in the United State...